



(51) International Patent Classification:

A61K 39/215 (2006.01) C12N 15/62 (2006.01)

(21) International Application Number:

PCT/EP2021/073542

(22) International Filing Date:

25 August 2021 (25.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2013385.6	26 August 2020 (26.08.2020)	GB
2101435.2	02 February 2021 (02.02.2021)	GB

(71) Applicant: **SCANCELL LIMITED** [GB/GB]; John Eccles House Robert Robinson Avenue, Oxford Science Park, Oxford Oxfordshire OX4 4GP (GB).

(72) Inventors: **DURRANT, Linda Gillian**; c/o Scancell Limited, John Eccles House, Robert Robinson Avenue, Oxford Science Park, Oxford Oxfordshire OX4 4GP (GB). **VANKEMMELBEKE, Mireille**; c/o Scancell Limited, John Eccles House, Robert Robinson Avenue, Oxford Science Park, Oxford Oxfordshire OX4 4GP (GB). **BRENTVILLE, Victoria**; c/o Scancell Limited, John Eccles House, Robert Robinson Avenue, Oxford Science Park,


Oxford Oxfordshire OX4 4GP (GB). **METHERINGHAM, Rachael**; c/o Scancell Limited, John Eccles House, Robert Robinson Avenue, Oxford Science Park, Oxford Oxfordshire OX4 4GP (GB).

(74) Agent: **KILBURN & STRODE LLP** et al.; Lacon London 84 Theobalds Road, London WC1X 8NL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NUCLEIC ACIDS ENCODING A POLYPEPTIDE COMPRISING A MODIFIED FC REGION OF A HUMAN IGG1 AND AT LEAST ONE HETEROLOGOUS ANTIGEN



(57) Abstract: The present invention relates to nucleic acids and peptides encoded by those nucleic acids. In particular, the peptides comprise a modified IgG1 Fc region and one or more heterologous epitopes, which may be B- or T-cell epitopes. A nucleic acid of the invention may encode a polypeptide comprising: (i) a modified Fc region of a human IgG1, and (i) at least one heterologous antigen, wherein (a) the modified Fc region comprises at least the part of Fc that is capable of binding to CD64 and/or TRIM21, (b) at least one residue of the Fc region is modified to the corresponding residue from a mouse IgG3 antibody and (c) the modified Fc region has enhanced avidity for Fc- gamma receptor (FcγR) when compared to the corresponding wildtype Fc region.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*